LTP

LTR PHARMA FPO [LTP]
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
Healthcare · ASX Small Cap
$0.4650 -3.1%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 3 consecutive scansFirst seen: 2026-03-19
Get alerts when LTP triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track LTP — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Volume surging at 2.5x normal while price falls — heavy selling pressure
  • Smart money may be accumulating — volume is flowing in even though price hasn't moved yet
  • Sitting near support — this level has held before and could attract buyers again
  • Drifting lower — down 8.8% over the last 5 days
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Adequate cash runway (7 quarters)
  • Very high P/S ratio (118.0x)
  • Revenue in sharp decline (-38%)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Altman Z-Score distress zone (1.67 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • MACD crossed bearish — momentum is fading
  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -38% — the top line is shrinking

Expected next for LTP

28 Oct 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 21 Oct to 4 Nov
The last 8 moved LTP -3.7% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

NONE Application for quotation of securities - LTP
NONE LTR Expands Men's Health Portfolio with KYZATREX Pilot
NONE FY26 Results Announcement
LOW Investor Presentation

Recent ASX Announcements

2026-09-04 Application for quotation of securities - LTP
2026-09-02 Investor Presentation
2026-08-31 LTR Expands Men's Health Portfolio with KYZATREX Pilot
2026-08-27 FY26 Results Announcement PRICE SENSITIVE
2026-08-27 Appendix 4G and Corporate Governance Statement

Key Metrics

$85.4M
Market Cap
130K
Avg Volume
2.5x
Vol Ratio
$0.35 — $0.81
52-Week Range
0.1%
Short Interest
N/A
Cash Runway
-54.7%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 59%
LLeader vs LaggardlaggardRS: -14
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:LTP vs NUZLTP vs IPDLTP vs HIQ
Share this analysis

Track LTP and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required